Left Ventricular Hypertrophy in Hypertension: Its Arrhythmogenic Potential

Overview

Journal Heart

Date 2005 Jan 20

PMID 15657259

Citations 57

Authors

Thomas Kahan

Lennart Bergfeldt

Affiliations

Soon will be listed here.

Citing Articles

New perspectives in the echocardiographic hemodynamics multiparametric assessment of patients with heart failure.

Lisi M, Luisi G, Pastore M, Mandoli G, Benfari G, Ilardi F Heart Fail Rev. 2024; 29(4):799-809.

PMID: 38507022 PMC: 11189326. DOI: 10.1007/s10741-024-10398-7.

Cardiovascular Manifestations and Management in ADPKD.

Sagar P, Rangan G Kidney Int Rep. 2023; 8(10):1924-1940.

PMID: 37850017 PMC: 10577330. DOI: 10.1016/j.ekir.2023.07.017.

Hypersensitive C-reactive protein as a potential indicator for predicting left ventricular hypertrophy in elderly community-dwelling patients with hypertension.

Song W, Zhang C, Tang J, Li Y, Jiao T, Lin X BMC Cardiovasc Disord. 2023; 23(1):480.

PMID: 37759159 PMC: 10537845. DOI: 10.1186/s12872-023-03509-z.

Left ventricular hypertrophy and mortality in ethnic minority groups in the UK: e-ECHOES study.

Shantsila E, Shantsila A, Williams N, Lip G, Gill P J Hypertens. 2023; 42(1):95-100.

PMID: 37706514 PMC: 10712994. DOI: 10.1097/HJH.0000000000003561.

Hypertensive Heart Disease: A Narrative Review Series-Part 2: Macrostructural and Functional Abnormalities.

Nemtsova V, Burkard T, Vischer A J Clin Med. 2023; 12(17).

PMID: 37685790 PMC: 10488346. DOI: 10.3390/jcm12175723.

References

Lim P, Nys M, Naas A, Struthers A, Osbakken M, MacDonald T . Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension. 1999; 33(2):713-8. DOI: 10.1161/01.hyp.33.2.713. View

Kahan T . The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl. 1998; 16(7):S23-9. View

Brilla C, Funck R, Rupp H . Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000; 102(12):1388-93. DOI: 10.1161/01.cir.102.12.1388. View

Vakili B, Okin P, Devereux R . Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001; 141(3):334-41. DOI: 10.1067/mhj.2001.113218. View

Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P . Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus.... J Hypertens. 2002; 20(4):657-63. DOI: 10.1097/00004872-200204000-00023. View

. New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias. Eur Heart J. 2002; 22(23):2148-63. DOI: 10.1053/euhj.2001.3036. View

Malmqvist K, Kahan T, Edner M, Bergfeldt L . Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol. 2002; 90(10):1107-12. DOI: 10.1016/s0002-9149(02)02777-7. View

Lips D, deWindt L, van Kraaij D, Doevendans P . Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J. 2003; 24(10):883-96. DOI: 10.1016/s0195-668x(02)00829-1. View

Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder R . A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003; 115(1):41-6. DOI: 10.1016/s0002-9343(03)00158-x. View

10.

Schlaich M, Kaye D, Lambert E, Sommerville M, Socratous F, Esler M . Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003; 108(5):560-5. DOI: 10.1161/01.CIR.0000081775.72651.B6. View

11.

Pacifico A, Henry P . Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol. 2003; 14(7):764-75. DOI: 10.1046/j.1540-8167.2003.02543.x. View

12.

Lindholm L, Dahlof B, Edelman J, Ibsen H, Borch-Johnsen K, Olsen M . Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet. 2003; 362(9384):619-20. DOI: 10.1016/S0140-6736(03)14183-9. View

13.

Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux R . Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003; 16(11 Pt 1):895-9. DOI: 10.1016/s0895-7061(03)01018-5. View

14.

Koren M, Devereux R, Casale P, Savage D, LARAGH J . Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991; 114(5):345-52. DOI: 10.7326/0003-4819-114-5-345. View

15.

Weber K, Brilla C, Campbell S, Guarda E, Zhou G, Sriram K . Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993; 88 Suppl 1:107-24. DOI: 10.1007/978-3-642-72497-8_8. View

16.

Hart G . Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res. 1994; 28(7):933-46. DOI: 10.1093/cvr/28.7.933. View

17.

Gonzalez-Juanatey J, Garcia-Acuna J, Pose A, Varela A, Calvo C, Cabezas-Cerrato J . Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol. 1998; 81(2):170-4. DOI: 10.1016/s0002-9149(97)00869-2. View

18.

Karpanou E, Vyssoulis G, Psichogios A, Malakou C, Kyrozi E, Cokkinos D . Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J. 1998; 136(5):765-8. DOI: 10.1016/s0002-8703(98)70119-x. View

19.

Messerli F . Hypertension and sudden cardiac death. Am J Hypertens. 2000; 12(12 Pt 3):181S-188S. DOI: 10.1016/s0895-7061(99)00106-5. View